US Edition
The US will buy 2 million doses of an HIV prevention drug for low-income countries
The U.S. will provide 2 million doses of lenacapavir, a twice-yearly HIV prevention drug, to low-income countries by 2028 under the PEPFAR program to reduce new infections.
- On Thursday, the U.S. State Department said the government will buy lenacapavir doses under PEPFAR to cover up to 2 million people in low-income countries by 2028 and work with governments on distribution.
- After foreign aid cuts earlier this year, advocates asked about disruptions as the Trump administration slashed aid, causing health clinic closures and protesters near the White House on Sept. 2, 2025, highlighted withheld PEPFAR funds.
- Clinical trials last year showed lenacapavir offered near-complete protection, with over 99% of people at high risk of HIV remaining negative and each injection lasting six months.
- Gilead Sciences will provide lenacapavir at no profit and has signed agreements with generic drug manufacturers, while the U.S. will buy and supply doses to local governments as a stopgap until generics arrive.
- PEPFAR's long-term investment—more than $120 billion—paired with UNAIDS warnings highlights risks of more than six million new infections and 4.2 million AIDS-related deaths if cut amid 1.3 million new infections annually worldwide.
37 Articles
37 Articles
Associated Press News
The US will buy 2 million doses of an HIV prevention drug for low-income countries
The U.S. is purchasing enough doses of a new twice-a-year HIV prevention shot to share with up to 2 million people in poor countries by 2028.
Washington – Despite massive cuts to aid programs, the US government intends to fund an international program for affordable access to a drug to prevent HIV. The State Department in Washington justified its decision to promote the distribution of the drug lenacapavir yesterday by arguing that this would...
PEPFAR and Gilead Collaborate to Expand Access to Lenacapavir for HIV Prevention
The President’s Emergency Plan for AIDS Relief (PEPFAR) and Gilead Sciences revealed plans to purchase injectable lenacapavir for HIV prevention (PrEP) in countries with the highest HIV/AIDS burdens, focusing on preventing transmission from mothers to their children. Mitchell Warren, the executive director of the AIDS Vaccine Advocacy Coalition (AVAC), a global HIV prevention organization, remarked, “Prevention programs were absolutely gutted.” …
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
